On Sep 15, we issued an updated research report on Latham, NY-based AngioDynamics Inc. (ANGO). The company is expected to maintain focus on exclusive technology that offers superior outcome and ...

The extension of the agreement is a part of the company’s plan to tap the $420 million CVC market and bring disruptive technologies into the Vascular Access space. Interface Biologics has been working ...

The BioFlo 320, next-generation bioprocess control station, is designed as a universal platform capable of meeting the ever changing needs of all segments of the biotech and pharmaceutical sciences.

Therapeutic and diagnostic devices maker, AngioDynamics Inc. ( ANGO) recently received 510(k) approval from the U.S. Food and Drug Administration (FDA) for its BioFlo peripherally inserted central ...

You probably haven’t heard of this medical device maker, AngioDynamics (ANGO), but its sturdy upbeat performance amid the market’s fickle behavior in recent weeks deserves investor attention. The ...

Leading life science company Eppendorf introduces the BioFlo 120, their latest bench scale fermentor/bioreactor system for research and development. This flexible instrument is capable of microbial ...

ENFIELD, Conn.--(BUSINESS WIRE)-- The BioFlo 320 is truly a step into the future for Eppendorf as a bioprocess equipment manufacturer. New features including autoclavable and single-use vessel ...

Leading life science company Eppendorf introduces the BioFlo 120, their latest bench scale fermentor/bioreactor system for research and development. This flexible instrument is capable of microbial ...

On Sep 15, we issued an updated research report on Latham, NY-based AngioDynamics Inc. ( ANGO). The company is expected to maintain focus on exclusive technology that offers superior outcome and ...

Eppendorf North America, Inc. Hauppauge, NY, February 2015 The BioFlo 320 is truly a step into the future for Eppendorf as a bioprocess equipment manufacturer. New features including autoclavable and ...